<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34518331</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>75</StartPage><EndPage>81</EndPage><MedlinePgn>75-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2021-327133</ELocationID><Abstract><AbstractText Label="BACKGROUND">Premorbid body mass index, physical activity, diabetes and cardiovascular disease have been associated with an altered risk of developing amyotrophic lateral sclerosis (ALS). There is evidence of shared genetic risk between ALS and lipid metabolism. A very large prospective longitudinal population cohort permits the study of a range of metabolic parameters and the risk of subsequent diagnosis of ALS.</AbstractText><AbstractText Label="METHODS">The risk of subsequent ALS diagnosis in those enrolled prospectively to the UK Biobank (n=502&#x2009;409) was examined in relation to baseline levels of blood high and low density lipoprotein (HDL, LDL), total cholesterol, total cholesterol:HDL ratio, apolipoproteins A1 and B (apoA1, apoB), triglycerides, glycated haemoglobin A1c (HbA1c) and creatinine, plus self-reported exercise and body mass index.</AbstractText><AbstractText Label="RESULTS">Controlling for age and sex, higher HDL (HR 0.84, 95%&#x2009;CI 0.73 to 0.96, p=0.010) and apoA1 (HR 0.83, 95% CI 0.72 to 0.94, p=0.005) were associated with a reduced risk of ALS. Higher total cholesterol:HDL was associated with an increased risk of ALS (HR 1.17, 95% CI 1.05 to 1.31, p=0.006). In models incorporating multiple metabolic markers, higher LDL or apoB was associated with an increased risk of ALS, in addition to a lower risk with higher HDL or apoA. Coronary artery disease, cerebrovascular disease and increasing age were also associated with an increased risk of ALS.</AbstractText><AbstractText Label="CONCLUSIONS">The association of HDL, apoA1 and LDL levels with risk of ALS contributes to an increasing body of evidence that the premorbid metabolic landscape may play a role in pathogenesis. Understanding the molecular basis for these changes will inform presymptomatic biomarker development and therapeutic targeting.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Alexander G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0003-1063-3277</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5490-1697</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK martin.turner@ndcn.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_17228</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>CH/1996001/9454</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T006927/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_QA137853</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C505693">APOA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C569471">APOB protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016632">Apolipoprotein A-I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053299">Apolipoprotein B-100</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001055">Apolipoproteins B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016632" MajorTopicYN="N">Apolipoprotein A-I</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053299" MajorTopicYN="N">Apolipoprotein B-100</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001055" MajorTopicYN="N">Apolipoproteins B</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008076" MajorTopicYN="N">Cholesterol, HDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008075" MajorTopicYN="N">Lipoproteins, HDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040242" MajorTopicYN="N">Risk Reduction Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cholesterol</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>14</Day><Hour>5</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34518331</ArticleId><ArticleId IdType="pmc">PMC8685635</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2021-327133</ArticleId><ArticleId IdType="pii">jnnp-2021-327133</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A, Calvo A, Chio A, et al. . Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 2014;13:1108&#x2013;13. 10.1016/S1474-4422(14)70219-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70219-4</ArticleId><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K, Feneberg E, Scaber J, et al. . Amyotrophic lateral sclerosis: the complex path to precision medicine. J Neurol 2018;265:2454&#x2013;62. 10.1007/s00415-018-8983-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8983-8</ArticleId><ArticleId IdType="pmc">PMC6182683</ArticleId><ArticleId IdType="pubmed">30054789</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, et al. . Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013;41:118&#x2013;30. 10.1159/000351153</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Swash M. The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey. J Neurol Neurosurg Psychiatry 2015;86:667&#x2013;73. 10.1136/jnnp-2014-308946</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-308946</ArticleId><ArticleId IdType="pmc">PMC4453495</ArticleId><ArticleId IdType="pubmed">25644224</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Reilly &#xc9;J., Wang H, Weisskopf MG, et al. . Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:205&#x2013;11. 10.3109/21678421.2012.735240</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.735240</ArticleId><ArticleId IdType="pmc">PMC3615420</ArticleId><ArticleId IdType="pubmed">23134505</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Deng J, Jaffa M, et al. . Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 2011;44:20&#x2013;4. 10.1002/mus.22114</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22114</ArticleId><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Wotton C, Talbot K, et al. . Cardiovascular fitness as a risk factor for amyotrophic lateral sclerosis: indirect evidence from record linkage study. J Neurol Neurosurg Psychiatry 2012;83:395&#x2013;8. 10.1136/jnnp-2011-301161</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-301161</ArticleId><ArticleId IdType="pubmed">22072701</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja NA, van der Schouw YT, Fischer K, et al. . Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011;82:638&#x2013;42. 10.1136/jnnp.2010.236752</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.236752</ArticleId><ArticleId IdType="pubmed">21471184</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MHB, Seelen M, de Jong SW, et al. . Lifetime physical activity and the risk of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013;84:976&#x2013;81. 10.1136/jnnp-2012-304724</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304724</ArticleId><ArticleId IdType="pubmed">23418211</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F, H&#xe5;llmarker U, James S, et al. . Amyotrophic lateral sclerosis among cross-country skiers in Sweden. Eur J Epidemiol 2016;31:247&#x2013;53. 10.1007/s10654-015-0077-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-015-0077-7</ArticleId><ArticleId IdType="pubmed">26220522</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian TH, Glascow N, Barry ADF, et al. . Physical exercise is a risk factor for amyotrophic lateral sclerosis: convergent evidence from mendelian randomisation, transcriptomics and risk genotypes. EBioMedicine 2021;68:103397. 10.1016/j.ebiom.2021.103397</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103397</ArticleId><ArticleId IdType="pmc">PMC8170114</ArticleId><ArticleId IdType="pubmed">34051439</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou M-A, Rotem RS, Seals RM, et al. . Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol 2015;72:905&#x2013;11. 10.1001/jamaneurol.2015.0910</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.0910</ArticleId><ArticleId IdType="pmc">PMC4975611</ArticleId><ArticleId IdType="pubmed">26030836</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, et al. . Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol 2015;22:1436&#x2013;42. 10.1111/ene.12632</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12632</ArticleId><ArticleId IdType="pmc">PMC4506907</ArticleId><ArticleId IdType="pubmed">25600257</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Lu C-J, Chen R-C, et al. . Risk of amyotrophic lateral sclerosis in patients with diabetes: a nationwide population-based cohort study. J Epidemiol 2015;25:445&#x2013;51. 10.2188/jea.JE20140176</Citation><ArticleIdList><ArticleId IdType="doi">10.2188/jea.JE20140176</ArticleId><ArticleId IdType="pmc">PMC4444499</ArticleId><ArticleId IdType="pubmed">25947580</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Hammar N, Malmstr&#xf6;m H, et al. . Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol 2017;81:718&#x2013;28. 10.1002/ana.24936</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24936</ArticleId><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum Mol Genet 2019;28:688&#x2013;97. 10.1093/hmg/ddy384</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy384</ArticleId><ArticleId IdType="pmc">PMC6360326</ArticleId><ArticleId IdType="pubmed">30445611</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Hemani G, et al. . Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol 2019;85:470&#x2013;81. 10.1002/ana.25431</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25431</ArticleId><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Breslow NE. Statistics in epidemiology: the case-control study. J Am Stat Assoc 1996;91:14&#x2013;28. 10.1080/01621459.1996.10476660</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1996.10476660</ArticleId><ArticleId IdType="pubmed">12155399</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen N, Sudlow C, Downey P, et al. . UK Biobank: current status and what it means for epidemiology. Health Policy Technol 2012;1:123&#x2013;6. 10.1016/j.hlpt.2012.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlpt.2012.07.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ainsworth BE, Haskell WL, Herrmann SD, et al. . 2011 compendium of physical activities: a second update of codes and MET values. Med Sci Sports Exerc 2011;43:1578&#x2013;81. 10.1249/MSS.0b013e31821ece12</Citation><ArticleIdList><ArticleId IdType="doi">10.1249/MSS.0b013e31821ece12</ArticleId><ArticleId IdType="pubmed">21681120</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradbury KE, Guo W, Cairns BJ, et al. . Association between physical activity and body fat percentage, with adjustment for BMI: a large cross-sectional analysis of UK biobank. BMJ Open 2017;7:e011843. 10.1136/bmjopen-2016-011843</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-011843</ArticleId><ArticleId IdType="pmc">PMC5372047</ArticleId><ArticleId IdType="pubmed">28341684</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, et al. . Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol 2018;84:130&#x2013;9. 10.1002/ana.25276</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray E, Thompson AG, Wuu J, et al. . CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 2020;7:1296&#x2013;306. 10.1002/acn3.51114</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51114</ArticleId><ArticleId IdType="pmc">PMC7448184</ArticleId><ArticleId IdType="pubmed">32666680</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelli WP, Anderson K, Wilson PW, et al. . Lipids and risk of coronary heart disease. study. Ann Epidemiol 1992;2:23&#x2013;8. 10.1016/1047-2797(92)90033-M</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/1047-2797(92)90033-M</ArticleId><ArticleId IdType="pubmed">1342260</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie-Martin S, Jones A, Iacoangeli A, et al. . UK case control study of smoking and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2020;21:222&#x2013;7. 10.1080/21678421.2019.1706580</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1706580</ArticleId><ArticleId IdType="pmc">PMC7261396</ArticleId><ArticleId IdType="pubmed">32301340</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan Y, Fang F. Smoking and amyotrophic lateral sclerosis: a Mendelian randomization study. Ann Neurol 2019;85:482&#x2013;4. 10.1002/ana.25443</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25443</ArticleId><ArticleId IdType="pubmed">30786056</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie-Martin S, Wootton RE, Budu-Aggrey A, et al. . Relationship between smoking and ALS: Mendelian randomisation interrogation of causality. J Neurol Neurosurg Psychiatry 2020;91:1312&#x2013;5. 10.1136/jnnp-2020-323316</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323316</ArticleId><ArticleId IdType="pubmed">32848012</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo V, Bueno-De-Mesquita HB, Vermeulen R, et al. . Smoking and risk for amyotrophic lateral sclerosis: analysis of the EPIC cohort. Ann Neurol 2009;65:378&#x2013;85. 10.1002/ana.21653</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21653</ArticleId><ArticleId IdType="pubmed">19399866</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira M, Gromicho M, Henriques A, et al. . Cardiovascular comorbidities in amyotrophic lateral sclerosis. J Neurol Sci 2021;421:117292. 10.1016/j.jns.2020.117292</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117292</ArticleId><ArticleId IdType="pubmed">33423011</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou M-A, Seals RM, Gredal O, et al. . Cardiovascular disease and diagnosis of amyotrophic lateral sclerosis: a population based study. Amyotroph Lateral Scler Frontotemporal Degener 2016;17:548&#x2013;54. 10.1080/21678421.2016.1208247</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1208247</ArticleId><ArticleId IdType="pmc">PMC5178102</ArticleId><ArticleId IdType="pubmed">27436717</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737&#x2013;41. 10.1161/01.ATV.8.6.737</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.8.6.737</ArticleId><ArticleId IdType="pubmed">3196218</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Goldacre R, Talbot K, et al. . Cerebrovascular injury as a risk factor for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2016;87:244&#x2013;6. 10.1136/jnnp-2015-311157</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311157</ArticleId><ArticleId IdType="pmc">PMC4789816</ArticleId><ArticleId IdType="pubmed">26260352</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb BA, Verden A, Messner AK, et al. . Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA's adverse event reporting system. Drug Saf 2018;41:403&#x2013;13. 10.1007/s40264-017-0620-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-017-0620-4</ArticleId><ArticleId IdType="pubmed">29427042</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, et al. . Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol 2020;27:1010&#x2013;6. 10.1111/ene.14190</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14190</ArticleId><ArticleId IdType="pubmed">32097525</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, O'Reilly &#xc9;ilis J, Cortese M, et al. . Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2021;22:133&#x2013;43. 10.1080/21678421.2020.1822411</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1822411</ArticleId><ArticleId IdType="pmc">PMC8004541</ArticleId><ArticleId IdType="pubmed">32985910</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Chen L, Zhan Y, et al. . Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology 2020;94:e1835&#x2013;44. 10.1212/WNL.0000000000009322</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009322</ArticleId><ArticleId IdType="pmc">PMC7274849</ArticleId><ArticleId IdType="pubmed">32221024</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Ilardi A, et al. . Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 2009;73:1681&#x2013;5. 10.1212/WNL.0b013e3181c1df1e</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df1e</ArticleId><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ikeda K, Hirayama T, Takazawa T, et al. . Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med
2012;51:1501&#x2013;8
https://www.ncbi.nlm.nih.gov/pubmed/22728481
10.2169/internalmedicine.51.7465
</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.51.7465</ArticleId><ArticleId IdType="pubmed">22728481</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, K&#xfc;hnlein P, Hendrich C, et al. . Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 2011;258:613&#x2013;7. 10.1007/s00415-010-5805-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5805-z</ArticleId><ArticleId IdType="pubmed">21128082</ArticleId></ArticleIdList></Reference><Reference><Citation>De Aguilar JLG. Lipid biomarkers for amyotrophic lateral sclerosis. Front Neurol 2019;10:248. 10.3389/fneur.2019.00284</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00284</ArticleId><ArticleId IdType="pmc">PMC6458258</ArticleId><ArticleId IdType="pubmed">31019485</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Misawa K, Tohnai G, et al. . A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. Commun Biol 2020;3:526. 10.1038/s42003-020-01251-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-01251-2</ArticleId><ArticleId IdType="pmc">PMC7511394</ArticleId><ArticleId IdType="pubmed">32968195</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Ou R, Wei Q, et al. . Shared genetic links between amyotrophic lateral sclerosis and obesity-related traits: a genome-wide association study. Neurobiol Aging 2021;102:211.e1:211&#x2013;211.e9. 10.1016/j.neurobiolaging.2021.01.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2021.01.023</ArticleId><ArticleId IdType="pubmed">33640203</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrikoula M, McDowell IFW. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. Diabetes Obes Metab 2008;10:271&#x2013;8. 10.1111/j.1463-1326.2007.00714.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1463-1326.2007.00714.x</ArticleId><ArticleId IdType="pubmed">18333887</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiniakou I, Drakos E, Sinatkas V, et al. . High-density lipoprotein attenuates Th1 and Th17 autoimmune responses by modulating dendritic cell maturation and function. J Immunol 2015;194:4676&#x2013;87. 10.4049/jimmunol.1402870</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1402870</ArticleId><ArticleId IdType="pmc">PMC4417411</ArticleId><ArticleId IdType="pubmed">25870241</ArticleId></ArticleIdList></Reference><Reference><Citation>White CR, Datta G, Giordano S. High-density lipoprotein regulation of mitochondrial function. Adv Exp Med Biol 2017;982:407&#x2013;29. 10.1007/978-3-319-55330-6_22</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-55330-6_22</ArticleId><ArticleId IdType="pmc">PMC5822681</ArticleId><ArticleId IdType="pubmed">28551800</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta MB, Saha S, Mohanty PK, et al. . Increased expression of ApoA1 after neuronal injury may be beneficial for healing. Mol Cell Biochem 2017;424:45&#x2013;55. 10.1007/s11010-016-2841-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-016-2841-8</ArticleId><ArticleId IdType="pubmed">27734225</ArticleId></ArticleIdList></Reference><Reference><Citation>Munaf&#xf2; MR, Tilling K, Taylor AE, et al. . Collider scope: when selection bias can substantially influence observed associations. Int J Epidemiol 2018;47:226&#x2013;35. 10.1093/ije/dyx206</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyx206</ArticleId><ArticleId IdType="pmc">PMC5837306</ArticleId><ArticleId IdType="pubmed">29040562</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rensen HT, Riis AH, Lash TL, et al. . Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes 2010;3:413&#x2013;7. 10.1161/CIRCOUTCOMES.110.936278</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.110.936278</ArticleId><ArticleId IdType="pubmed">20530788</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, van Veenhuijzen K, van der Spek RA, et al. . Associations between lifestyle and amyotrophic lateral sclerosis stratified by C9orf72 genotype: a longitudinal, population-based, case-control study. Lancet Neurol 2021;20:373&#x2013;84. 10.1016/S1474-4422(21)00042-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00042-9</ArticleId><ArticleId IdType="pubmed">33894192</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, O'Reilly &#xc9;ilis J, Weisskopf MG, et al. . Smoking and risk of amyotrophic lateral sclerosis: a pooled analysis of 5 prospective cohorts. Arch Neurol 2011;68:207&#x2013;13. 10.1001/archneurol.2010.367</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.367</ArticleId><ArticleId IdType="pmc">PMC3319086</ArticleId><ArticleId IdType="pubmed">21320987</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, et al. . Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010;81:385&#x2013;90. 10.1136/jnnp.2009.183525</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Fry A, Littlejohns TJ, Sudlow C, et al. . Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol 2017;186:1026&#x2013;34. 10.1093/aje/kwx246</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwx246</ArticleId><ArticleId IdType="pmc">PMC5860371</ArticleId><ArticleId IdType="pubmed">28641372</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Regod&#xf3;n Wallin A, Samuelsson K, et al. . The Swedish Motor Neuron Disease Quality Registry. Amyotroph Lateral Scler Front Degener 2018;19:528&#x2013;37. 10.1080/21678421.2018.1497065</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1497065</ArticleId><ArticleId IdType="pubmed">30296856</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology 2007;68:1002&#x2013;7. 10.1212/01.wnl.0000258551.96893.6f</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000258551.96893.6f</ArticleId><ArticleId IdType="pubmed">17389304</ArticleId></ArticleIdList></Reference><Reference><Citation>Horrocks S, Wilkinson T, Schnier C, et al. . Accuracy of routinely-collected healthcare data for identifying motor neurone disease cases: a systematic review. PLoS One 2017;12:e0172639. 10.1371/journal.pone.0172639</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0172639</ArticleId><ArticleId IdType="pmc">PMC5330471</ArticleId><ArticleId IdType="pubmed">28245254</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>